Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).

Viatris’ presbyopia drug MR-141 (phentolamine ophthalmic solution 0.75%) has met the primary endpoint and all secondary ...

Lipocine has initiated subject dosing in a two-arm, blinded, randomised Phase III trial of LPCN 1154 for postpartum ...

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.